The case in one table

The lawsuit is Federal Trade Commission et al. v. Hims & Hers Health, Inc., No. 3:26-cv-07871-VC, in the U.S. District Court for the Northern District of California. Judge Vince Chhabria has had it since August 14, 2026. Here is what has happened, taken from the court docket and the parties' own statements.

FTC et al. v. Hims & Hers: key dates (court docket and party statements read November 8, 2026; FTC release of November 10, 2026 verified by search November 21, 2026)
DateWhat happenedSource
October 2023FTC sends Hims a civil investigative demand, according to Hims' own filingHims 10-Q, August 10, 2026
July 29, 2026FTC, the Utah Division of Consumer Protection and the People of California (through the Los Angeles County Counsel) file suit; Hims calls the claims "baseless"FTC press release; Hims statement
August 14, 2026Case reassigned to Judge ChhabriaDocket
August 18, 2026Unredacted complaint filed after the court rejected Hims' request to keep parts sealedDocket
August 24, 2026Court warns that another overbroad sealing request will bring sanctionsDocket
October 22, 2026Hims files a motion to dismissDocket
October 30, 2026Initial case management conference heldDocket
November 10, 2026Amended complaint adds Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs, alongside Utah and California; FTC's case page lists the case as pendingFTC press release
November 25 and December 17, 2026Plaintiffs' opposition and Hims' reply due (set before the amended complaint; may change)Docket
January 14, 2027 (per Hims' 10-Q filed November 9, 2026; the docket earlier showed January 7)Hearing on the motion to dismissDocket

As of November 8, 2026, the docket shows no ruling on the motion, no settlement and no amended complaint. Everything below that describes Hims' conduct is an allegation the plaintiffs must still prove.

What does the FTC say Hims did?

The complaint groups its claims around four practices. The FTC's July 29 press release summarizes each one, and the complaint adds detail.

Charging before a real consultation

Hims advertises access to licensed providers. The FTC's answer is blunt: "The FTC alleges, however, that Hims does not give most consumers a consultation with a provider." According to the complaint, after a consumer filled in the intake form, a provider prescribed without offering a consultation, and Hims then charged the consumer immediately and enrolled them in a subscription, without the consumer first reviewing or approving the treatment. Utah's press release frames it the same way: "Hims promised a free consult and secure care."

Refills you were not clearly told about

The FTC says Hims "fails to clearly and conspicuously inform consumers when their prescriptions will be refilled each month." For a subscription product, the refill date is the billing date, so this claim is really about when your card gets charged.

A cancel button that was hard to find

Before 2023, according to the complaint, most consumers could cancel only through phone, email or chat. After that, an online cancel button existed, but, in the FTC's words, "the button appeared only after these consumers selected an option to 'add/remove items from order'." The plaintiffs argue that this falls short of the simple cancellation that federal law requires for subscriptions.

Health data shared with advertising platforms

The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties, through at least May 2024. The complaint describes roughly 14 million email addresses uploaded to Meta for ad targeting between September 2020 and June 2023. This is the part of the case the FTC's headline emphasizes: its release is titled "FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices."

Which laws are involved, and what are the plaintiffs asking for?

The unredacted complaint (docket entry 28) lists nine counts under five laws. The November 10, 2026 amended complaint, which added five states as co-plaintiffs, is not reflected in the table below.

Counts in the unredacted complaint, filed August 18, 2026
CountsLawBrought byCovers
I–IIIFTC Act, Section 5FTCPrivacy deception, failure to disclose data sharing, deceptive intake and consultation claims
IV–VIRestore Online Shoppers' Confidence Act (ROSCA)FTCDisclosure of terms, express informed consent before charging, simple cancellation
VII–VIIICalifornia False Advertising Law and Unfair Competition LawPeople of CaliforniaSame conduct under state law
IXUtah Consumer Sales Practices ActUtah Division of Consumer ProtectionSame conduct under state law

The plaintiffs ask for an injunction, money for consumers, disgorgement in Utah and civil penalties of up to $2,500 per violation under each of two California statutes. The complaint does not name a total. It does not bring claims under the FTC's Health Breach Notification Rule, and it does not allege that any Hims medication was unsafe or ineffective.

What does Hims say?

On the day the suit was filed, Hims said: "We are confident in our position and will vigorously defend ourselves against these baseless claims." It added that the suit ignored evidence from a nearly three-year investigation.

Its quarterly report for the period ending June 30, 2026, filed with the SEC on August 10, gives more context. Hims wrote that "the Company engaged in good faith settlement negotiations with the FTC, but these negotiations were unsuccessful," and that "as of June 30, 2026, the Company had recorded a legal contingency accrual of approximately $60 million for this matter." An accrual is an accounting estimate of a probable cost, not an admission or a settlement figure. The same report discloses a separate SEC Enforcement investigation, opened in February 2026, about Hims' statements on compounded semaglutide.

The motion to dismiss, filed October 22 by the law firm Keker, Van Nest & Peters, argues in part that "Plaintiffs cannot manufacture deception by ignoring what H&H told consumers, or create liability by rewriting ROSCA." In other words, Hims says its disclosures were adequate and that the plaintiffs read the subscription law too broadly.

What has the court done so far?

Very little on the merits, which is normal at this stage. The court's sharpest words so far came over secrecy. After Hims asked to seal large parts of the complaint, the judge declined and, on August 24, wrote: "If Hims files another sealing request that is remotely this overbroad, sanctions will issue." The court also denied Hims' request to postpone the first case management conference, which went ahead on October 30.

In a joint statement filed October 23, the parties proposed a schedule: amendments as of right by November 12, 2026, fact discovery closing June 24, 2027, and a hearing on dispositive motions on February 10, 2028. Those dates were proposals; we could not see whether the court adopted them. The parties also said they were open to a settlement conference after fact discovery. Four related private lawsuits against Hims sit before the same judge.

Alleged versus established

Status of the main claims as of November 8, 2026 (court docket)
ClaimStatus
Most customers did not get a provider consultation before being chargedAlleged; disputed by Hims; no finding
Monthly refill dates were not clearly disclosedAlleged; no finding
Online cancellation was hidden behind "add/remove items"Alleged; no finding
Health data went to Meta and Snap through at least May 2024Alleged; no finding
Hims accrued about $60 million for the matterEstablished by Hims' own SEC filing
Settlement talks failed before the suitEstablished by Hims' own SEC filing

Does the case change what Hims sells?

Not directly. The lawsuit is about billing, cancellation and data practices, not about which drugs Hims offers. Hims changed its GLP-1 offering earlier for other reasons. On March 9, 2026, it told investors it would "no longer advertise compounded GLP-1 offerings on its platform or in its marketing," that existing patients would have "the opportunity to transition to FDA-approved medicines," and that compounded semaglutide would remain available on a limited scale when a provider decides it is clinically necessary.

When we last read Hims' weight-loss page, on September 17, 2026, it listed brand medications from $149 a month and a required membership of $39 for the first month, then $149 a month. Hims blocked our re-reads in October and November, so check the current figures on its site. Our Hims & Hers review has the full price table.

What this means for you

If you are a Hims customer, the lawsuit does not change your prescription or your account today. It is a reminder to check the things the complaint is about, which are worth checking with any subscription program.

If you are choosing a program now, compare what each one tells you before you pay. The table below comes from our transparency index and shows which of the ten programs we review print cancellation and refund terms on the page itself.

Cancellation and refund disclosure on the programs' own pages (reads of September 17 to November 8, 2026; see the transparency index for dates per program)
ProgramCancellation terms on the pageRefund terms on the page
NexLifeYes: takes effect after 30 days; one more shipment may be chargedYes: shipped orders final; guarantee policy with conditions
Mochi Health"Cancel anytime"Link only
Noom Med"Cancel anytime"Not on the page
RoStart fee refunded if not eligible; rest not recordedSame
CalibrateThree-month minimum statedNot shown
Found, Henry Meds, Form HealthLink onlyLink only
Hims & HersNot in our read (September 17)Not in our read

NexLife, which pays this site commissions, prints the most here, but a 30-day cancellation delay is itself a cost: on a $129 month-to-month tirzepatide plan, one extra shipment is $129. Read every program's terms with that kind of arithmetic in mind. Our NexLife cancellation explainer walks through it.

What to watch next

We will update this page when the docket changes. For other dated developments, see the news ledger; for the wider question of what online reviews of these programs can tell you, see Can you trust GLP-1 telehealth reviews?

Frequently asked questions

What does the FTC lawsuit against Hims & Hers allege?

The FTC, Utah and Los Angeles County sued Hims & Hers in federal court in San Francisco on July 29, 2026, alleging it charged and enrolled most consumers without a provider consultation, did not clearly disclose monthly refills, made online cancellation hard and shared health data with advertising platforms. An amended complaint filed November 10, 2026 added Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs. These are allegations, not findings. Hims moved to dismiss on October 22, 2026, and its November 9 quarterly report gave a January 14, 2027 hearing date. No ruling had been filed; the FTC lists the case as pending.

Is Hims & Hers still operating while the FTC case is pending?

Yes. A lawsuit does not stop a company from operating, and the court has issued no injunction. Hims continues to sell memberships and medications, and said on July 29, 2026 that it would vigorously defend itself. Customers' prescriptions and accounts are not changed by the case itself.

Can Hims customers get money back from the FTC case?

Not yet. The plaintiffs ask for money for consumers, but money is paid only if the FTC wins or the parties settle, and neither has happened as of November 8, 2026. If a refund program is ever created, the FTC usually announces it on ftc.gov and contacts eligible customers; it never charges a fee to claim a refund.

Does the lawsuit say Hims' GLP-1 medications are unsafe?

No. The complaint is about billing, subscription and cancellation practices, consultation claims and the sharing of health data with advertising platforms. It does not allege that Hims' medications were unsafe or ineffective. Hims separately disclosed an SEC investigation into its past statements about compounded semaglutide.

What happens at the January 14, 2027 hearing?

Judge Vince Chhabria will hear arguments on Hims' motion to dismiss, filed October 22, 2026. He can dismiss some or all counts, deny the motion so the case moves into discovery, or let the plaintiffs amend. A ruling may come at the hearing or later in writing.

Why does the $60 million figure matter?

In its quarterly report for the period ending June 30, 2026, Hims said it had recorded a legal contingency accrual of approximately $60 million for the FTC matter after settlement talks failed. An accrual is an accounting estimate of a probable cost. It is not an admission and not a settlement amount.

Sources

  1. FTC: Five states join FTC lawsuit alleging Hims & Hers engaged in deceptive and unlawful privacy practices — November 10, 2026; verified by search November 21, 2026 (ftc.gov returns 404 to automated clients)
  2. FTC press release: FTC and States Act Against Hims & Hers for Deceptive and Unlawful Privacy Practices — July 29, 2026; read November 8, 2026
  3. FTC v. Hims & Hers: complaint as filed (redacted PDF, FTC) — filed July 29, 2026; the unredacted version is docket entry 28 (August 18, 2026); verified by search November 21, 2026
  4. Court docket, No. 3:26-cv-07871-VC (N.D. Cal.), CourtListener — entries through November 4, 2026; read November 8, 2026
  5. Joint case management statement (PDF) — filed October 23, 2026; read November 8, 2026
  6. Hims & Hers statement responding to the FTC lawsuit — July 29, 2026; read November 8, 2026
  7. Hims & Hers Form 10-Q for the quarter ended June 30, 2026 (SEC) — filed August 10, 2026; read November 8, 2026
  8. Hims & Hers press release on compounded GLP-1s (Form 8-K exhibit) — March 9, 2026; read November 8, 2026
  9. Hims & Hers to announce third-quarter 2026 results on November 9 — October 12, 2026; read November 8, 2026
  10. Utah Department of Commerce: Utah sues Hims & Hers — July 29, 2026; read November 8, 2026

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.